Comparison of the Prognostic Outcome between High-Grade Ovarian Sertoli-Leydig Cell Tumors (SLCTs) and Low-Grade SLCTs

Abstract

The purpose of the current study was to compare prognostic outcomes between patients with high-grade ovarian Sertoli-Leydigcell tumors (SLCTs) and those with other low-grade SLCTs. We retrospectively reviewed medical records for 24 patients pathologicallydiagnosed with SLCTs between 2006 to 2019 at two institutions. The patients were grouped according to pathological grade:SLCT was classified as grade 1, well differentiated; grade 2, intermediated differentiated; or grade 3, poorly differentiated (Meyer’sclassification). Statistical analysis was performed to compare survival outcomes according to pathological grade. The median patientage was 42.5 years (range 16–75). Eighteen patients (75%) were International Federation of Gynecology and Obstetrics stageI, and none were diagnosed in stage IV. Nine patients (37.5%) were grade 3, and 15 patients (63.5%) were grades 1–2. When comparingclinical baseline characteristics of the grade 1–2 group with those of the grade 3 group, only serum CA125 level at diagnosiswas significantly higher in the grade 3 group (38.34 vs. 382.29, p=0.002). Five patients experienced recurrence of grade 3 disease,while no recurrence was reported in grade 1–2 disease. Four of the five recurrent patients died. In result, grade 3 ovarian SLCTshowed significantly poorer prognosis than grade 1–2 disease (overall survival, hazard ratio=14.25, 95% confidence interval=1.881–108.0; log-rank p=0.010). Our findings were consistent with the concept that patients with stage I/grade 1–2 tumors have agood prognosis without adjuvant chemotherapy. Since grade 3 ovarian SLCT appears to be relatively more fatal than grade 1 or 2,patients with grade 3 SLCT might require more aggressive surgical intervention and post-treatment surveillance.